$5.18-0.12 (-2.26%)
Strata Critical Medical, Inc.
Strata Critical Medical, Inc. in the Healthcare sector is trading at $5.18 with a market capitalization of $512M. Wall Street consensus targets $9.25 (4 analysts), implying a +78.6% move over the next 12 months. The stock is currently 20% below its 52-week high of $6.50, remaining 4.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $67.38M↑ | $66.79M↑ | $49.30M↓ | $70.80M↑ | $35.95M |
| Gross Profit | $14.12M↑ | $11.67M↑ | $11.61M↓ | $17.74M↑ | $7.05M |
| Operating Income | -$2.97M↑ | -$6.41M↓ | -$5.62M↓ | -$4.95M↑ | -$5.68M |
| Net Income | $2.15M↑ | -$8.83M↓ | $57.42M↑ | -$3.74M↓ | -$3.49M |
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground tr...
Strata Critical Medical, Inc. (SRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strata Critical Medical is back in focus after an updated fair value estimate of $9.13, up from $8.81, reset expectations around what the stock might be worth on a modeled basis. That change comes alongside fresh Street commentary, where several firms have launched bullish coverage and one has lifted its price target by $0.25, tying their views to revised growth and profitability assumptions. As you read on, you will see how these shifting targets and narratives could shape how you follow...
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...
Joby Aviation reported better-than-expected first-quarter sales. Joby is still, essentially, presales. Joby stock gained 21% to $10.52 on Wednesday, while the and rose 1.5% and 1.2%, respectively.
Moby summary of Strata Critical Medical, Inc.'s Q1 2026 earnings call